Knockdown of CDKN1A Suppresses the IL-17 Pathway to Inhibit Oxidative Stress and Alleviate Autism Spectrum Disorder.

This comprehensive study employed multi-omics bioinformatics and in vivo experiments to uncover the pivotal role of CDKN1A in autism spectrum disorder (ASD) pathogenesis. The researchers established an ASD rat model and found that CDKN1A knockdown significantly improved social interaction, reduced anxiety, and enhanced spatial learning, by suppressing the IL-17 pathway and mitigating neuroinflammation and oxidative stress. These findings establish CDKN1A as a promising therapeutic target for ASD, paving the way for groundbreaking treatments. Limitations include the need for further validation in human studies and exploration of additional molecular mechanisms.